[1] Aziz MA, Wright A, Laszlo A, De Muynck A, Portaels F, Van Deun A, Wells C, Nunn P, Blanc L, Raviglione M; WHO/International Union Against Tuberculosis And Lung Disease Global Project on Anti-tuberculosis Drug Resistance Surveillance. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-tuberculosis Drug Resistance Surveillance): an updated analysis [J]. Lancet, 2006, 368: 2142-2154.
[2] Maher D, Raviglione M. Global epidemiology of tuberculosis [J]. Clin Chest Med, 2005,26(2):167-182.
[3] 严碧涯,端木宏谨.结核病学[M].北京:北京出版社,2003:594.
[4] 林辉,刘洁,陈林,王志斌,靖宽和,沈静,詹建,熊鸿燕,曹佳.重庆市2003—2006年肺结核病耐药情况分析[J]. 第三军医大学学报,2008,30:1183-1185.
[5] Namaei MH, Sadeghian A, Naderinasab M, Ziaee M. Prevalence of primary drug resistant Mycobacterium tuberculosis in Mashhad, Iran [J]. Indian J Med Res, 2006,124(1):77-80.
[6] Rao NA, Irfan M, Hussain SJ. Primary drug resistance against Mycobacterium tuberculosis in Karachi [J]. J Pak Med Assoc, 2008,58(3):122-125.
[7] Yew WW,Leung CC. Management of multidrug-resistant tuberculosis: update 2007 [J]. Respirology,2008,13(1):21-46.
[8] Lew W, Pai M, Oxlade O, Martin D, Menzies D. Initial drug resistance and tuberculosis treatment outcomes: systematic review and meta-analysis [J]. Ann Intern Med, 2008,149(2):123-134.
[9] Watterson SA, Wilson SM, Yates MD, Drobniewski FA. Comparison of three molecular assays for rapid detection of rifampin resistance in Mycobacterium tuberculosis [J]. J Clin Microbiol, 1998,36(7):1969-1973.
|